{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:34:44Z","timestamp":1777937684398,"version":"3.51.4"},"reference-count":36,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Natalizumab is associated with a risk of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients infected with John Cunningham virus (JCV). Ocrelizumab has demonstrated efficacy to treat MS; however, its safety in patients previously treated with natalizumab is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate the safety and efficacy of ocrelizumab in patients with relapsing MS (RMS) previously treated with natalizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Clinically and radiographically stable RMS patients, ages 18\u201365 treated with natalizumab for \u2a7e 12 months, were enrolled in the study and initiated ocrelizumab 4\u20136 weeks after their final dose of natalizumab. Relapse assessment, expanded disability status scale, and brain magnetic resonance imaging (MRI) were performed prior to starting ocrelizumab and at months 3, 6, 9, and 12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Forty-three patients were enrolled, and 41 (95%) completed the study. Two patients had a relapse while on ocrelizumab, one at month 9 and the other at month 12, without changes on brain MRI. Two additional patients had new brain MRI lesions detected at month 3, with no new symptoms. Thirteen serious adverse events (SAEs) were recorded, four of which were considered possibly related to ocrelizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Overall, our study indicates clinical and MRI stability for most patients transitioning from natalizumab to ocrelizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov Identifier:<\/jats:title>\n                    <jats:p>NCT03157830<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13524585231175284","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T05:11:11Z","timestamp":1686805871000},"page":"956-966","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE)"],"prefix":"10.1177","volume":"29","author":[{"given":"Kyle","family":"Smoot","sequence":"first","affiliation":[{"name":"Providence Brain and Spine Institute, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horia","family":"Marginean","sequence":"additional","affiliation":[{"name":"Providence Brain and Spine Institute, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Gervasi-Follmar","sequence":"additional","affiliation":[{"name":"Providence Brain and Spine Institute, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6636-5203","authenticated-orcid":false,"given":"Chiayi","family":"Chen","sequence":"additional","affiliation":[{"name":"Providence Brain and Spine Institute, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavle","family":"Repovic","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley","family":"Cohan","sequence":"additional","affiliation":[{"name":"Providence Brain and Spine Institute, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-322326"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103995"},{"key":"e_1_3_3_5_2","doi-asserted-by":"crossref","unstructured":"Khoy K Mariotte D Defer G et al. Natalizumab in multiple sclerosis treatment: From biological effects to immune monitoring. Front Immunol 2020; 11. https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.549842 (accessed 27 March 2023).","DOI":"10.3389\/fimmu.2020.549842"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22128"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577721"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10676-6"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30282-X"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107829"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.1200"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.02.028"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24651"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01037-2"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.257"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000388"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01672-9"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70021-3"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/20552173211013831"},{"key":"e_1_3_3_21_2","unstructured":"Highlights of perscribing information: Ocrevus. https:\/\/www.gene.com\/download\/pdf\/ocrevus_prescribing.pdf (2022 accessed 15 November 2022)."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_3_23_2","first-page":"799","article-title":"Acute multiple sclerosis relapse","volume":"22","author":"Berkovich RR","year":"2016","unstructured":"Berkovich RR. Acute multiple sclerosis relapse. Continuum (Minneap Minn) 2016; 22: 799\u2013814.","journal-title":"Continuum (Minneap Minn)"},{"key":"e_1_3_3_24_2","unstructured":"E6(R2) good clinical practice: Integrated addendum to IHC E6(R1): Guidance for industry. https:\/\/www.fda.gov\/media\/93884\/download (2018 accessed 15 November 2022)."},{"key":"e_1_3_3_25_2","unstructured":"WHO Director-General\u2019s opening remarks at the media briefing on COVID-19 \u2013 11 March 2020. https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19\u201411-march-2020 (accessed 27 March 2023)."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000355"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000809"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/20552173211066588"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.07.005"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201029"},{"key":"e_1_3_3_31_2","unstructured":"tysabri prescribing information. https:\/\/www.tysabri.com\/content\/dam\/commercial\/tysabri\/pat\/en_us\/pdf\/tysabri_prescribing_information.pdf (2021 accessed 27 March 2023)."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012700"},{"key":"e_1_3_3_33_2","article-title":"Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab","volume":"8","author":"Toorop AA","year":"2020","unstructured":"Toorop AA, Lierop ZYG, van Strijbis EEM, et al. Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab. Neurol Neuroimmunol Neuroinflamm 2020; 8: e904.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2021.1886924"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008189"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61649-8"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516634871"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585231175284","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585231175284","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585231175284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:12:05Z","timestamp":1777695125000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585231175284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1177\/13524585231175284"],"URL":"https:\/\/doi.org\/10.1177\/13524585231175284","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]}}}